SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
ACCESSWIRE - Mon Oct 05, 8:03AM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.
BUYINS.NET: SVA, TKC, BKF, VC, PRTS, GXC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Sep 29, 8:10AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Sernova Corp (NASDAQ:SVA), Turkcell Iletisim Hizmetleri AS (NYSE:TKC), iShares MSCI BRIC Index Fund (NYSE:BKF), Visteon Corp (NYSE:VC), US Auto Parts Network Inc (NASDAQ
VC: 106.48 (+0.30), PRTS: 2.16 (-0.01), TKC: 9.46 (-0.09), SVA: 5.07 (-0.02), GXC: 75.01 (-0.17), BKF: 32.40 (+0.05)
Sernova Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 21, 3:01PM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a leading clinical stage, regenerative medicine company developing biologically compatible, implantable medical device and therapeutic cellular technologies is pleased to announce it has been listed for trading on the OTCQB market exchange in the United States under the symbol "SEOVF".
SVA.VN: 0.310 (-0.020)
Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies
Marketwired - Thu Sep 10, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a license agreement with the University Health Network (UHN) of Toronto, Canada to gain exclusive worldwide rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.
SVA.VN: 0.310 (-0.020)
Sernova Corp. Announces Collaboration with Massachusetts General Hospital to Develop Novel Diabetes Treatment with Funding Support from JDRF
Marketwired - Tue Jul 07, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH), is pleased to announce a research collaboration with Massachusetts General Hospital, supported with funding from JDRF to develop a novel treatment for diabetes.
SVA.VN: 0.310 (-0.020)
Sernova Grants Stock Options
Marketwired - Fri Jun 26, 4:01PM CDT
SERNOVA CORP. (the "Company"
SVA.VN: 0.310 (-0.020)
Sernova Receives Issued Patent in the United States for Its Cell Pouch(TM) and Therapeutic Cell Transplantation Technologies
Marketwired - Thu Apr 23, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued Sernova a patent that helps protect Sernova's entire Cell Pouch System (TM).
SVA.VN: 0.310 (-0.020)
Sernova is Awarded Patents in Multiple Countries for Cell Pouch(TM) and Therapeutic Cell Transplantation Technologies
Marketwired - Thu Feb 12, 5:14AM CST
Sernova Corp. (TSX VENTURE: SVA), today announced that the Patent Offices in China, Israel, Singapore and New Zealand have issued Notices of Allowance and issued patents to Sernova for its patent application entitled "Methods and Devices for Cellular Transplantation."
SVA.VN: 0.310 (-0.020)
Sernova to Participate in Biotech Showcase(TM) 2015 Healthcare Conference in San Francisco
Marketwired - Mon Jan 12, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA), announced today that Dr. Philip Toleikis, Ph.D., president and CEO will be participating in the Biotech Showcase(TM) healthcare conference being held in San Francisco, CA January 12-14, 2015.
SVA.VN: 0.310 (-0.020)
Sernova Provides Corporate Update
Marketwire Canada - Mon Nov 10, 5:35AM CST
Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing cell therapy technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and hemophilia, today provides a corporate update, summarizing advances made in the clinical development of its Cell Pouch(TM) over the past 12 months and the application of its technologies to new disease indications.
SVA.VN: 0.310 (-0.020)
PMT, BPOPM, EXAS, SVA, SGG Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Perpetual Energy Inc (NYSE
SGG: 32.24 (+0.53), PMT: 15.97 (-0.03), EXAS: 8.51 (+0.71), SVA: 5.07 (-0.02), BPOPM: 19.08 (+0.24)